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Investing in the Future of Cardiovascular TechnologyChristopher Colecchi, BA, MPH, David Tancredi, MD, PHDSUMMARYFro
pre
MaTranslational investigators and companies face a challenging economic environment when seeking funds to move
pre-clinical stage research into human testing and beyond. Speciﬁcally, funding for cardiovascular research and product
development is difﬁcult to secure, whether from the NIH, venture capitalists, or industry. But new funding models for
advancing patient-oriented science to the commercial sector are emerging. Boston-based Broadview Ventures, created by
the LeducqFamilyTrust, promotes thedevelopment of technology for thediagnosis and treatment of cardiovascular disease
and stroke through direct equity-based investments. It targets early stage companies seeking to fund proof-of-concept for
technologies that hold promise as future breakthroughs for patient care.With 27 such investments over the last seven years,
Broadviewhas considerable experience in the seed/early-stage space, and its investmentmodel is demonstrating early signs
of success. Broadview actively seeks collaborations with world-class translational investigators, inventors, and their com-
panies, andwelcomes scientiﬁc inquiries, discussion and proposals for funding. (J AmColl Cardiol Basic Trans Sci 2016;1:87–
93) © 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).F or translational investigators in cardiovasculardisease and stroke, securing funds to movepre-clinical stage research into human testing
and beyond remains a challenge. This “translational
funding gap” is widening, and although many claim
to fund early stage work, the data and experience of
entrepreneurs in academia and elsewhere prove
differently (Figure 1) (1). Despite recent increases in
funding for translational research, the National Insti-
tutes of Health primarily supports basic discovery
research, and has experienced signiﬁcant budget
pressure over the past years. Indeed, cardiovascular
and stroke research continue to be relatively under-
funded with respect to their impact on global
health—as compared with cancer, for example (2,3)—
and foundations and charitable organizations such
as the American Heart Association can only make up
some of this difference (Figure 2). In industry over
the last decade, spending on research andm Broadview Ventures, Boston, Massachusetts. Mr. Colecchi is the mana
sident of Broadview Ventures; and is the executive director of the Leduc
nuscript received January 14, 2016; revised manuscript received Januarydevelopment has remained unchanged, whereas the
cost to bring new drugs and devices to market is
increasing, making access to industry funding by in-
dependent clinical investigators more difﬁcult. And
the percentage of venture capital funding directed to-
ward start-up/seed investments is diminishing—with
venture capital preferring to fund later-stage, lower-
risk product development activities (Figure 3) (4).
The good news in this challenging picture is that
new funding models for advancing patient-oriented
science to the commercial sector are emerging. Fam-
ily ofﬁces, foundations, incubators, angel groups, and
others are stepping into new territory and directing
funds toward the translational gap to help develop
new therapies for patients (Figure 4) (5).
Boston-based Broadview Ventures is one such or-
ganization. Created by the Leducq Family Trust,
Broadview Ventures was designed to promote the
development of technology for the diagnosis andging director of Broadview Ventures. Dr. Tancredi is
q Foundation.
21, 2016, accepted January 27, 2016.
FIGURE 1 Translational Funding Gap
DoD ¼ Department of Defense; FY ¼ ﬁscal year; NIH ¼ National Institutes of Health; VC ¼ venture capital.
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88treatment of cardiovascular disease and stroke
through direct equity-based investments (cash in ex-
change for equity position). It targets early-stage
companies seeking to fund proof of concept for tech-
nologies that hold promise as future breakthroughs for
patient care. With 27 such investments over the last 7
years, Broadview has considerable experience in the
seed/early-stage space, and its investment model is
demonstrating early signs of success.FIGURE 2 Public and Private Funding for Cardiovascular Disease Tra
FY ¼ ﬁscal year; IPO ¼ initial public offering; M&A ¼ mergers and acquHISTORY: LEDUCQ FOUNDATION AND
BROADVIEW VENTURES
The mission and structure of Broadview Ventures
can be traced to the Leducq Foundation and its sup-
porting trust, created in 1996 by French entrepreneur
and industrialist Jean Leducq, together with his wife
Sylviane. Motivated by a multigenerational family
history of cardiovascular illness, and inspired to workils That of Cancer
isitions; R&D ¼ research and development.
FIGURE 3 VC Dollars Exist, But Are Predominantly Focused on De-Risked, Late-Stage Programs
VC ¼ venture capital.
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89at the international level through years of living and
working abroad, the Leducqs used the proceeds of the
sale of the family’s multinational linen and uniform
services businesses to establish a foundation for car-
diovascular research with a mission to improve hu-
man health through international efforts to combat
cardiovascular and neurovascular disease. The foun-
dation’s signature program, the Transatlantic Net-
works of Excellence in Cardiovascular and
Neurovascular Disease, supports international net-
works of experts in cardiovascular disease and stroke
that work collaboratively to advance scientiﬁcFIGURE 4 Start-Ups Are Turning to New Sources of Funding to Fill
CRO ¼ contract research organization; VC ¼ venture capital.knowledge, bring new technology to patient care, and
help to train early career investigators. Since making
its ﬁrst award in 1999, the foundation has committed
over $350 million to cardiovascular and neuro-
vascular research, supporting 47 research networks at
130 institutions in 19 countries.
From the outset, the Leducq organization was
interested in promoting the technology that was
developed through the research it supported. The
board of the Leducq Family Trust soon determined
that the best way to accomplish this objective was to
create an independent organization dedicated solelythe Gap
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90to promoting and investing in technology. In 2008, it
decided to create Broadview Ventures, speciﬁcally
addressing the translational gap by providing seed
and early-stage funding for companies on the path to
developing commercial products for patients with
cardiovascular and neurovascular disease. Broadview
shares a mission in cardiovascular and neurovascular
disease with the Leducq Foundation, but proceeds
through a direct investment model, whereas the
foundation works through a more traditional grant
program.
Broadview is purposefully structured as a for-
proﬁt venture capital ﬁrm so that it can interact
on equal ground with like-minded venture capital-
ists and corporate partners that have ﬁnancial re-
turn on investment as a primary goal. That said,
Broadview is mission-, not proﬁt-driven, and de-
ﬁnes success through social impact and improving
patient care. Its mission orientation allows Broad-
view to invest in important areas that others may
see as less interesting due to market size or risk
issues (e.g., pediatrics). The sole shareholder of
Broadview is the Leducq Family Trust, which can
manage both the risk and long-term capital com-
mitments associated with early-stage investing.
Broadview is structured as an evergreen fund and
all generated proﬁts are used for additional early
stage investments or to support activities of the
Leducq Foundation.FIGURE 5 Broadview Investments by Indication
AF ¼ atrial ﬁbrillation; CAD ¼ coronary artery disease; HF ¼ heart failure
arterial hypertension.BROADVIEW ACTIVITY
In sourcing investments, Broadview deﬁnes cardio-
vascular disease broadly. In addition to investing in
the core therapeutic areas within cardiovascular dis-
ease such as myocardial infarction, heart failure,
arrhythmias, and valvular disease, Broadview is also
interested in underlying pathways such as inﬂam-
mation and atherogenesis; predisposing factors such
as hypertension; and comorbidities such as car-
diorenal and cardiopulmonary conditions. Type 2
diabetes, obesity, and dyslipidemia, as cardiovascular
risk factors, are also considered to fall within the
scope of the mission. Stroke is the primary indication
within Broadview’s neurovascular focus.
The investments made thus far by Broadview
include microRNA, stem cell, and gene therapies;
nonsurgical and minimally invasive delivery tech-
niques for valves and devices; and mechanical and
pharmacological treatments for atrial ﬁbrillation,
hypertension, stroke, diabetes, and obesity (Figure 5).
Broadview invests in all technology platforms related
to its mission—diagnostics, therapeutics, and devices
(Figure 6). Five of its investments have been made to
support technology developed by grantees of the
Leducq Foundation.
Broadview receives approximately 300 proposals
annually and invests $1 million in 4 to 5 of these
opportunities each year. Broadview seeks high-; HTN ¼ hypertension; MI ¼ myocardial infarction; PAH ¼ pulmonary
FIGURE 6 Broadview Investments by Technology
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91impact science that has the potential to change the
practice of cardiology. To be considered for invest-
ment, the technology must have adequate intellec-
tual property protection and a clear ability to
inﬂuence patient therapy and/or standard of care.
The proposed use of funds must be well deﬁned with
quantiﬁable and achievable milestones. And there
must be a clear understanding of future funding
requirements to bring the technology through clinical
development to market.
Broadview is fortunate to be guided by a world-class
strategic advisory board composed of thought leaders
from academia, ﬁnance, and industry (Figure 7). It also
has access to a network of cardiovascular and neuro-
vascular medicine experts developed over the years
via the Leducq Foundation. Broadview utilizes these
relationships for deal sourcing, diligence, investment
counsel, clinical development advice, and portfolio
company guidance. Without a doubt, these thought
leaders have played a critical role in the development
and advancement of the Broadview Ventures invest-
ment model.
The Boston-based Broadview investment team, led
by Christopher Colecchi, consists of physicians, sci-
entists, and business professionals who oversee deal
sourcing, diligence, and the investment process. After
investment, the Broadview team plays an active role
via board participation, offering long-term support
throughout the life of its portfolio companies.
CASE STUDY
Although improving patient care is its main goal,
Broadview also hopes to share its learning and
experiences with other family ofﬁces and ventureFIGURE 7 2016 Broadview Strategic Advisory Board
Eugene Braunwald – Dis nguished Hersey Professor of M
TIMI Study Group at the Brigham and Women’s Hospital.
Kim Fox – Consultant Cardiologist and Director of Cardiolog
Clinical Cardiology, Imperial College.
Thomas Hughes – President and CEO of Zafgen, Inc. and D
member of several SABs, including Nimbus Discovery, LLC.
Jerry Karabelas – Partner at Care Capital and chairman of t
BioVenture fund and former CEO of Novar s Pharma.
Mar n Landaluce – President, Board of Directors of the Le
Joseph Loscalzo – Hersey Professor of the Theory and Prac
Chairman of the Department of Medicine and Physician-in-Ch
Director of the Brigham Biomedical Research Ins tute.
Eric Rose – Academic physician and entrepreneur, former S
Columbia, and Chairman of the Dept. of Surgery at Columbia
Life Sciences at MacAndrews & Forbes, and CEO of Siga Tech
David Tancredi – Execu ve Director, Leducq Foundaon,aphilanthropic investors. Although still evolving as a
fund, Broadview has seen some early signs of
success, most notably the recent acquisition by
Edwards Lifesciences of CardiAQ Valve Technologies,
a company funded by Broadview that is focused on
developing a percutaneous mitral valve technology.
The CardiAQ story demonstrates the many steps,
layers of funding and expertise, and persistence
necessary for successful early stage investing. In
2008, Broadview was connected with a surgeon
and business executive both working in their spare
hours to develop a percutaneous mitral valve im-
plantation device. Later that year, after a signiﬁcant
level of diligence and review by its strategic advisory
board, Broadview made a $750,000 seed invest-
ment in CardiAQ to develop a device prototype
and conduct early animal testing. This investment
attracted additional corporate and board leadershipedicine at Harvard Medical School, and Chairman of the
y at the Royal Brompton Hospital, and Professor of
irector on the Board of miRagen Therapeu cs, Inc. and
he board of several companies. Founder of Novar s
ducq Foundaon
ce of Medicine at Harvard Medical School, and
ief at the Brigham and Women's Hospital, and Vice
urgeon-in-Chief at the New York Presbyterian Hospital/
University, currently the Execu ve Vice President for
nologies, Inc.
nd President, Broadview Ventures
FIGURE 8 CardiAQ Valve Technologies: From Idea to First-In-Man
CEO ¼ chief executive ofﬁcer; CVT ¼ CardiAQ Valve Technologies.
FIGURE 9 Broadvi
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92from within the valve industry and led to a $5M
Series A ﬁnancing round in 2011 in which Broad-
view also participated. The company established
state-of-the-art facilities in Irvine, California, and
successfully completed the ﬁrst-ever transcatheter
mitral valve replacement in a porcine model. In 2012,
the company conducted successful ﬁrst-in-human
implantation of the valve in Europe. This milestone
attracted a large Series B ﬁnancing round with
participation by several large, well-known, venture
capital investors (OrbiMed, InVus, Versant, and
Advent). With this funding, a second-generation de-
vice was developed and successfully implanted in
several more patients. In August of 2015, Edwards
Lifesciences acquired CardiAQ Valve Technologies for
$400 million (Figure 8).
Although the ﬁnancial return on investment was
positive for all involved, most important to Broad-
view is that the technology, through Edwards’ marketew Ventures Contact Information
entures, Inc.
eet,
02110
44
Christopher Colecchi
Managing Director
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Nichole Schiﬀer
Manager of Opera ons
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www.broadviewventures.orgleadership and extensive resources, will now move to
large-scale clinical trials for regulatory approval—and
hopefully become a commercial product that will
improve the lives of patients with mitral valve dis-
ease. In addition, the investment story demonstrates
that mission-related, philanthropic-based funds can
be deployed at an early stage to help science cross the
translational gap to move through the clinical devel-
opment pathway.
For every dollar invested by Broadview, its
portfolio companies have raised seven additional
dollars in co-investments, follow-on funding, and
grants. This additional funding has enabled smaller
“surrogate markers of success” that demonstrate day-
to-day progress at Broadview’s portfolio companies—
such as movement from pre-clinical work to ﬁrst-in
human trials, achievement of regulatory approval
for products, and a successful European product
launch. In addition, many of Broadview portfolio
companies have developed relationships with stra-
tegic investors and industry partners to support
movement toward commercial product approval.
THE FUTURE
The leadership, vision, and resources of the Leducq
Family Trust have been critical to the ability of
Broadview to look past the near term for high-risk–
high-reward, longer-term solutions to today’s press-
ing problems in cardiovascular and neurovascular
disease. With early-stage investing in the life sciences
comes acceptance that the road for the fund and its
portfolio companies will be challenging. There will
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93be many failures to get to far fewer successes.
Importantly, however, this work remains consistent
with the vision and values of the founders, whose
bequest will ensure that the foundation and Broad-
view remain true to their mission in cardiovascular
and neurovascular science and will have the re-
sources to continue the good work that started with
the Leducq Foundation 20 years ago.
Broadview actively seeks collaborations with
world-class translational investigators, inventors, andtheir companies, and welcomes scientiﬁc inquiries,
discussion and proposals for funding (Figure 9). In-
vestigators seeking funding should send an executive
summary of their proposal to Broadview at the e-mail
address provided (Figure 9).
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